Paper36948506
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Siddiqui BA and 20 others. J Immunother Cancer, 2023. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Papers, record 36948506. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36948506
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Prostatic Neoplasms | Major topic |
| Male | |
| Humans | |
| Leukocytes, Mononuclear | |
| Antibodies, Monoclonal | |
| Immunosuppressive Agents | |
| Tumor Microenvironment |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P50 CA140388 | NCI NIH HHS | United States | P50CA140388 | PubMed and NIH |
Source NIH RePORTER
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29702148 | Immunomodulatory effects of CD38-targeting antibodies. | Immunol Lett | 2018 | https://conductscience.org/library/papers/29702148 | PubMed |
| 2 | 29231133 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29231133 | PubMed |
| 3 | 33329591 | CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity. | Front Immunol | 2020 | https://conductscience.org/library/papers/33329591 | PubMed |
| 4 | 34663638 | Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34663638 | PubMed |
| 5 | 35663534 | Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors. | J Immunother Precis Oncol | 2021 | https://conductscience.org/library/papers/35663534 | PubMed |
| 6 | 34655533 | Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34655533 | PubMed |
| 7 | 31324781 | Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. | Nat Commun | 2019 | https://conductscience.org/library/papers/31324781 | PubMed |
| 8 | 28321130 | Effective combinatorial immunotherapy for castration-resistant prostate cancer. | Nature | 2017 | https://conductscience.org/library/papers/28321130 | PubMed |
| 9 | 32302573 | Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. | Cell | 2020 | https://conductscience.org/library/papers/32302573 | PubMed |
| 10 | 25628399 | An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25628399 | PubMed |
| 11 | 25255802 | Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. | J Natl Cancer Inst | 2014 | https://conductscience.org/library/papers/25255802 | PubMed |
| 12 | 28596308 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Science | 2017 | https://conductscience.org/library/papers/28596308 | PubMed |
| 13 | 27222480 | Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. | Blood | 2016 | https://conductscience.org/library/papers/27222480 | PubMed |
| 14 | 29950727 | IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. | Nature | 2018 | https://conductscience.org/library/papers/29950727 | PubMed |
| 15 | 30589920 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30589920 | PubMed |
| 16 | 11179357 | Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor 1-deficient mice. | Infect Immun | 2001 | https://conductscience.org/library/papers/11179357 | PubMed |
| 17 | 28239471 | Gene expression markers of Tumor Infiltrating Leukocytes. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/28239471 | PubMed |
| 18 | 33046869 | Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. | Nat Med | 2020 | https://conductscience.org/library/papers/33046869 | PubMed |
| 19 | 28716061 | Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/28716061 | PubMed |
| 20 | 26289091 | Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. | Cancer Immunol Immunother | 2015 | https://conductscience.org/library/papers/26289091 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42846924 | The multifaceted roles of tumor-infiltrating plasma cells in cancer immunology. | Fundam Res | 2026 | https://conductscience.org/library/papers/42846924 | PubMed |
| 42806985 | Dual blockade of adenosine A2A and A2B receptors is required to reverse NECA-induced immunosuppression in human macrophages: Implications for cancer immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42806985 | PubMed |
| 42805760 | Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42805760 | PubMed |
| 42653263 | Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653263 | PubMed |
| 42022555 | Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42022555 | PubMed |
| 41870750 | CX3CL1-CX3CR1 signaling orchestrates malignant progression of prostate cancer through luminal progenitor-macrophage crosstalk. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/41870750 | PubMed |
| 41734994 | The path forward for T cell engagers in patients with prostate cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41734994 | PubMed |
| 41710886 | Regulating the regulators via targeting CD38 in the tumor microenvironment. | Front Immunol | 2026 | https://conductscience.org/library/papers/41710886 | PubMed |
| 41367012 | The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/41367012 | PubMed |
| 41020944 | Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41020944 | PubMed |
| 40422244 | Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy. | Cells | 2025 | https://conductscience.org/library/papers/40422244 | PubMed |
| 39633050 | Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. | Nature | 2025 | https://conductscience.org/library/papers/39633050 | PubMed |
| 39457618 | Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia. | Biomedicines | 2024 | https://conductscience.org/library/papers/39457618 | PubMed |
| 38605951 | New insights into the role of macrophages in cancer immunotherapy. | Front Immunol | 2024 | https://conductscience.org/library/papers/38605951 | PubMed |
| 38565910 | Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer. | Prostate Cancer Prostatic Dis | 2025 | https://conductscience.org/library/papers/38565910 | PubMed |
| 37958472 | Potential Associations between Vascular Biology and Hodgkin's Lymphoma: An Overview. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958472 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36948506
GET https://conductscience.org/api/papers/v1/36948506/authors?page=2